Nanobiotix S.A.
NBTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.18 | -0.10 | 2.42 |
| FCF Yield | -15.57% | -5.29% | -31.14% | -12.17% |
| EV / EBITDA | -2.27 | -9.18 | -2.97 | -4.59 |
| Quality | ||||
| ROIC | -510.92% | -54.77% | -176.97% | -71.91% |
| Gross Margin | 100.00% | 100.00% | 79.38% | 100.00% |
| Cash Conversion Ratio | 0.29 | 0.31 | 0.65 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 139.16% | 357.12% | 238.91% |
| Free Cash Flow Growth | -59.21% | 65.55% | -23.56% | -8.90% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | 1.04 | -0.27 | 0.83 |
| Interest Coverage | -8.46 | -3.35 | -8.00 | -78.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.33 | 0.00 |
| Cash Conversion Cycle | -268.35 | 29.91 | -160.03 | 955.04 |